
ASH 2025 | 3-year follow-up results from the STARGLO trial of Glofit-GemOx vs R-GemOx in R/R DLBCL
During the 67th American Society of Hematology (ASH) Annual Meeting and Exposition, December 6–9, 2025, Orlando, US, the Lymphoma Hub was pleased to speak with Haifaa Abdulhaq, University of California, San Francisco, US. We asked, What do the 3-year follow-up results from the STARGLO trial tell us about glofitamab (Glofit) + gemcitabine + oxaliplatin (GemOx) treatment in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL).
In this interview, Abdulhaq discusses 3-year follow-up results from the phase III STARGLO trial (NCT04408638) of Glofit-GemOx vs rituximab…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.